Hercules, Calif. and Houston, Texas, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, and ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) a global leader in life science research and clinical diagnostics products, today announced a collaboration agreement with Oncocyte Corporation (Nasdaq ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), announced the launch of four new Droplet Digital™ PCR (ddPCR™) platforms. The newly introduced instruments include Bio-Rad’s QX Continuum™ ddPCR ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that in two studies ...
Are you new to quantitative (or “real-time”) PCR? Maybe you’re just looking to brush up on the basics of designing and analyzing qPCR experiments. Perhaps your reactions aren’t working. Again.
Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the CFX Opus Deepwell Dx Real-Time PCR System, ...
ddPCR reportedly provides quantification of target molecules with unprecedented precision and sensitivity. Bio-Rad Laboratories purchased QuantaLife for $162 million in cash plus future milestone ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), provides an overview of advances supporting the Company’s overall corporate strategy to improve science and healthcare in the year to date. Centered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results